Caisse DE Depot ET Placement DU Quebec Reduces Holdings in DexCom, Inc. (NASDAQ:DXCM)

Caisse DE Depot ET Placement DU Quebec reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,662 shares of the medical device company's stock after selling 114,661 shares during the quarter. Caisse DE Depot ET Placement DU Quebec's holdings in DexCom were worth $1,607,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares during the last quarter. Jennison Associates LLC boosted its position in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock valued at $594,455,000 after acquiring an additional 710,858 shares in the last quarter. Norges Bank bought a new stake in DexCom in the fourth quarter valued at $385,367,000. Northern Trust Corp lifted its holdings in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after purchasing an additional 91,051 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on DXCM. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Canaccord Genuity Group upped their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Citigroup increased their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.11.

DexCom Stock Up 2.2 %

Shares of NASDAQ:DXCM traded up $1.82 on Wednesday, hitting $83.35. 3,944,543 shares of the company traded hands, compared to its average volume of 4,294,290. The stock has a 50 day simple moving average of $71.05 and a 200-day simple moving average of $77.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $132.26. The company has a market cap of $32.68 billion, a PE ratio of 58.29, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.